spironolactone has been researched along with Pancreatic Neoplasms in 8 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Excerpt | Relevance | Reference |
---|---|---|
"Gemcitabine mono-therapy was carried out in an unresectable pancreatic cancer." | 5.33 | [A case of pancreatic cancer complicated by gemcitabine-induced peripheral edema]. ( Hirata, N; Ishiguro, A; Munakata, M; Sakata, Y; Shitara, K; Wada, R; Yabu, K, 2005) |
"However, in TRAIL-resistant pancreatic cancer, responsiveness to TRAIL treatment is terribly poor." | 1.48 | Chaetospirolactone reverses the apoptotic resistance towards TRAIL in pancreatic cancer. ( Gao, Y; Hu, W; Jia, X; Zhang, Q, 2018) |
"Gemcitabine mono-therapy was carried out in an unresectable pancreatic cancer." | 1.33 | [A case of pancreatic cancer complicated by gemcitabine-induced peripheral edema]. ( Hirata, N; Ishiguro, A; Munakata, M; Sakata, Y; Shitara, K; Wada, R; Yabu, K, 2005) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (50.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (12.50) | 29.6817 |
2010's | 3 (37.50) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hu, W | 1 |
Jia, X | 1 |
Gao, Y | 1 |
Zhang, Q | 2 |
Drzayich Antol, D | 1 |
Waldman Casebeer, A | 1 |
Khoury, R | 1 |
Michael, T | 1 |
Renda, A | 1 |
Hopson, S | 1 |
Parikh, A | 1 |
Stein, A | 1 |
Costantino, M | 1 |
Stemkowski, S | 1 |
Bunce, M | 1 |
Nevo, N | 1 |
Abu-Abeid, S | 1 |
Hazzan, D | 1 |
Lahat, G | 1 |
Nachmani, I | 1 |
Eldar, SM | 1 |
Zhang, L | 1 |
Xia, X | 1 |
Zhong, Y | 1 |
Xie, D | 1 |
Liu, S | 1 |
Wang, X | 1 |
Tu, J | 1 |
Faconti, L | 1 |
Mills, CE | 1 |
Govoni, V | 1 |
Gu, H | 1 |
Morant, S | 1 |
Jiang, B | 1 |
Cruickshank, JK | 1 |
Webb, AJ | 1 |
Lin, J | 1 |
Wu, YJ | 1 |
Liang, X | 1 |
Ji, M | 1 |
Ying, HM | 1 |
Wang, XY | 1 |
Sun, X | 1 |
Shao, CH | 1 |
Zhan, LX | 1 |
Zhang, Y | 1 |
Czamara, K | 1 |
Karnas, E | 1 |
Majka, Z | 1 |
Wojcik, T | 1 |
Zuba-Surma, EK | 1 |
Baranska, M | 1 |
Kaczor, A | 1 |
Liu, X | 1 |
Zhou, F | 1 |
Yang, Y | 1 |
Wang, W | 1 |
Niu, L | 1 |
Zuo, D | 1 |
Li, X | 1 |
Hua, H | 1 |
Zhang, B | 1 |
Kou, Y | 1 |
Guo, J | 1 |
Kong, F | 1 |
Pan, W | 1 |
Gao, D | 1 |
Meves, JM | 1 |
Sun, H | 1 |
Xue, M | 1 |
Wang, Y | 1 |
Tang, R | 1 |
Iso, T | 1 |
Haruyama, H | 1 |
Sunaga, H | 1 |
Matsui, H | 1 |
Matsui, M | 1 |
Tanaka, R | 1 |
Umbarawan, Y | 1 |
Syamsunarno, MRAA | 1 |
Putri, M | 1 |
Yamaguchi, A | 1 |
Hanaoka, H | 1 |
Negishi, K | 1 |
Yokoyama, T | 1 |
Kurabayashi, M | 1 |
Palomo-Briones, R | 1 |
Esquivel-González, S | 1 |
Aizpuru, A | 1 |
Gómez-Hernández, N | 1 |
Casas-Flores, S | 1 |
Barba de la Rosa, AP | 1 |
Arriaga, S | 1 |
Peterson, ME | 1 |
Carothers, MA | 1 |
Gamble, DA | 1 |
Rishniw, M | 1 |
Simó-Servat, A | 1 |
Peiró, I | 1 |
Villabona, C | 1 |
GEOKAS, MC | 1 |
CHUN, JY | 1 |
DINAN, JJ | 1 |
BECK, IT | 1 |
Shitara, K | 1 |
Ishiguro, A | 1 |
Munakata, M | 1 |
Sakata, Y | 1 |
Hirata, N | 1 |
Yabu, K | 1 |
Wada, R | 1 |
Moertel, CG | 1 |
Engstrom, P | 1 |
Lavin, PT | 1 |
Gelber, RD | 1 |
Carbone, PP | 1 |
Stephens, RL | 1 |
Hoogstraten, B | 1 |
Haas, C | 1 |
Clark, G | 1 |
Waddell, WR | 1 |
3 trials available for spironolactone and Pancreatic Neoplasms
Article | Year |
---|---|
Topics: Adult; Aged; Animals; Astrocytes; Bariatric Surgery; Beta vulgaris; Bioreactors; Biotechnology; Bloo | 2018 |
Chemotherapy of gastric and pancreatic carcinoma: a controlled evaluation of combinations of 5-fluorouracil with nitrosoureas and "lactones".
Topics: Adenocarcinoma; Antineoplastic Agents; Drug Therapy, Combination; Fluorouracil; Humans; Lomustine; N | 1979 |
Pancreatic cancer treated with carmustine, fluorouracil, and spironolactone: a randomized study.
Topics: Adult; Carmustine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middle Aged; Neopl | 1978 |
5 other studies available for spironolactone and Pancreatic Neoplasms
Article | Year |
---|---|
Chaetospirolactone reverses the apoptotic resistance towards TRAIL in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Drug Resistance, Neopla | 2018 |
Corticotropin secreting pancreatic neuroendocrine tumour, a therapeutic management challenge. A presentation of 2 cases.
Topics: ACTH Syndrome, Ectopic; Adrenocorticotropic Hormone; Chromogranins; Combined Modality Therapy; Embol | 2019 |
ISLET-CELL CARCINOMA (ZOLLINGER-ELLISON SYNDROME) WITH FULMINATING ADRENOCORTICAL HYPERFUNCTION AND HYPOKALEMIA.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adenoma, Islet Cell; Adrenalectomy; Adrenocortical Hyper | 1965 |
[A case of pancreatic cancer complicated by gemcitabine-induced peripheral edema].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Diuretics; Drug Administration Sched | 2005 |
Chemotherapy for carcinoma of the pancreas.
Topics: Adult; Aged; Autopsy; Biopsy; Carcinoma; Female; Fluorouracil; Humans; Laparotomy; Male; Middle Aged | 1973 |